Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01997346
Other study ID # AAAI1192
Secondary ID 1R01MH089831
Status Completed
Phase N/A
First received November 8, 2013
Last updated December 15, 2014
Start date November 2011
Est. completion date December 2011

Study information

Verified date December 2014
Source Columbia University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The availability of HIV care and treatment programs is increasing in sub-Saharan Africa. However more than half the patients who need HIV medicines are still not receiving this antiretroviral therapy (ART), and this can lead to early death from AIDS. One of the problems in this region is that patients start ART late, after the HIV disease is very advanced. This results in high death rates soon after ART initiation. The way clinic-level factors, such as the way services and referrals are organized, how referrals are regarded, counseling messages and record-keeping, contribute to late ART initiation is unclear. As the second phase of a 3-phase NIH-sponsored project, this study will identify clinic-level enablers and barriers to timely enrollment into HIV care and ART initiation. A cross-sectional qualitative study will be conducted at 4 selected HIV care and treatment clinics and the health facilities in which they are located in Ethiopia. Data will be collected using 4 methods:

1. Data abstraction

2. Key informant interviews with clinic personnel

3. Observation of post-test counseling sessions in the VCT clinic

4. Observation of provider-patient interactions in the care and treatment clinic Identifying modifiable health facility-level predictors of late ART initiation will facilitate implementation of interventions, programs and policies that will increase the number of patients who enroll in HIV care and initiate ART early. Additionally, results will inform the design of the third phase of the NIH-project referenced above.


Description:

Background: Although HIV care and treatment programs are scaling up in sub-Saharan Africa, more than 50% of patients who need ART are not receiving it and significant mortality from AIDS persists. One major challenge in this region is high rates of late ART initiation (i.e., in the advanced stages of HIV disease) which results in high rates of mortality soon after ART initiation. The clinic-level factors that contribute to late ART initiation are unclear.

Objective: As the second of a 3-phase NIH-sponsored project, this study aims to identify clinic-level enablers and barriers to timely ART initiation.

Methods: A cross-sectional qualitative study will be conducted at 4 purposively selected HIV care and treatment clinics in Ethiopia. Data will be collected using 4 methods:

1. Data abstraction

2. Key informant interviews with clinic personnel

3. Observation of post-test counseling sessions at the voluntary counseling and testing (VCT) clinic

4. Observation of provider-patient interactions in the care and treatment clinic Descriptive statistics will be produced from the data abstraction. Content analysis of key informant interviews will be conducted. Descriptive summaries will be produced from observations. All analyses will focus on identifying within- and across-clinic themes, and include triangulation across data collection methods to identify clinic-level enablers and barriers to timely ART initiation.

Expected use of results: Identifying modifiable clinic-level enablers and barriers to timely ART initiation will facilitate implementation of interventions, programs and policies to reduce late ART initiation. Additionally, results will inform the third phase of the NIH-project referenced above.


Recruitment information / eligibility

Status Completed
Enrollment 136
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility The inclusion and exclusion criteria for the clinics and the various study participants are given below:

1. Data abstraction

Inclusion criteria: N/A - all study sites included. Exclusion criteria: N/A - all study sites included. .

2. Key informant interviews

Inclusion criteria:

- =18 years of age;

- paid or voluntary employee in the 4 study sites for =6 months;

- and give verbal informed consent.

Exclusion criteria:

- <18 years of age;

- employed at the 4 study sites <6 months;

- and/or not willing to give verbal consent.

3. Observation of post-test counseling sessions in the VCT clinic

Inclusion criteria:

- Providers: =18 years of age; paid or voluntary employee in the 4 study sites for =6 months; responsible for HIV post-test counseling in VCT or PICT in the adult outpatient clinic; and give verbal informed consent

- Patients: =18 years of age; unaware of HIV status, and give verbal informed consent.

Exclusion criteria:

- Providers: <18 years of age; employed <6 months; and/or not willing to give verbal consent.

- Patients: <18 years of age; and/or not willing to give verbal consent.

4. Observation of provider-patient interactions in the care and treatment clinic

Inclusion criteria:

- Providers: =18 years of age; paid or voluntary employee in the care and treatment clinic of 4 study sites for =6 months; and give verbal consent.

- Patients: =18 years of age; not yet on ART (regardless of eligibility), receiving counseling or another service from one of the observed providers, and give verbal informed consent.

Exclusion criteria:

- Providers: <18 years of age; employed <6 months; and/or not willing to give verbal consent.

- Patients: <18 years of age; and/or not willing to give verbal consent.

Study Design

Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Locations

Country Name City State
Ethiopia Fitche Hospital Fitche
Ethiopia Goba Hospital Goba
Ethiopia Nekemte Hospital Nekemte
Ethiopia Shashemene Hospital Shashemene

Sponsors (2)

Lead Sponsor Collaborator
Columbia University National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

Ethiopia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of provider-patient interactions that were observed to be rushed by visit type Visit type includes post-test counseling, enrollment, 1st CD4, pre-ART monitoring, and ART preparatory. 12 months No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02511496 - Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia N/A
Completed NCT02234492 - The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients Phase 4
Completed NCT01685372 - Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults Phase 2
Completed NCT02027441 - Enhanced Prevention in Couples: Feasibility Study #2 N/A
Completed NCT02165202 - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis Phase 2
Completed NCT01449006 - A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac) Phase 4
Completed NCT02572401 - Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men N/A
Completed NCT01615601 - An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients Phase 4
Terminated NCT01448486 - A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV Phase 4
Completed NCT04122404 - POC Strategies to Improve TB Care in Advanced HIV Disease N/A
Completed NCT03290755 - Sexual Hepatitis C in HIV Positive Men Who Have Sex With Men (MSM) in Bordeaux
Completed NCT02974998 - Cape Town Young Women's Health CoOp N/A
Completed NCT01516970 - Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) Phase 3
Active, not recruiting NCT01875952 - Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL) Phase 4
Completed NCT01199939 - A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients Phase 2
Completed NCT03783130 - Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults Phase 1
Active, not recruiting NCT05657106 - Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk N/A
Not yet recruiting NCT05727033 - Extraordinarily Fun Training Project in Compulsory Secondary Education - Sexually Transmitted Infections N/A
Completed NCT01053741 - Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission N/A
Completed NCT02946047 - The Effect of Ixazomib on the Latent HIV Reservoir Phase 1/Phase 2